Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a single centre Window-of-Opportunity trial investigating the efficacy and
feasibility of short term imatinib in patients with newly diagnosed triple negative breast
cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any status in the axilla when
neoadjuvant treatment not is considered as an option.
The primary aim is to determine the proportion of patients that converts to estrogen receptor
(ER) positive breast cancer in the removed breast cancer tissue at surgery.
Phase:
N/A
Details
Lead Sponsor:
Vastra Gotaland Region
Collaborators:
Lund University Sahlgrenska University Hospital, Sweden